All News

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

Patrick A. Kenney, MD, and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.

According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.

The FDA has set a new Prescription Drug User Fee Act date of July 23, 2026, for subcutaneous isatuximab plus standard of care in multiple myeloma.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

Preliminary data from the phase 1/1b RMC-9805-001 study support continued development of zoldonrasib as a therapeutic strategy in this population.

Data from a phase 1 trial suggest that durable, vaccine-induced T-cell memory may be achievable even in pancreatic ductal adenocarcinoma.

Diane Simeone, MD, discussed results from the RASolute 302 trial, which showed improved overall survival with daraxonrasib vs SOC in metastatic PDAC.

Findings from a phase 1 trial showed no adverse effects higher than grade 3 among those who received ruxolitinib/abemaciclib for advanced myelofibrosis.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

New findings from the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Early trials exploring the efficacy of PD-1 blockade in Hodgkin lymphoma inspired the SWOG S1826 trial, which evaluated the agent with AVD in this population.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

All patients who received cilta-cel in the phase 2 CAR-PRISM trial achieved MRD negativity per next-generation sequencing.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.

The FDA has granted fast track designation to BBO-11818, an investigational pan-KRAS inhibitor, for advanced KRAS-mutant pancreatic ductal adenocarcinoma.

A numerical survival improvement was observed with ramucirumab plus pembrolizumab among those with squamous cell carcinoma in a phase 2 study.

Experts discussed the evolving landscape of EGFR-mutated NSCLC, focusing on the practice-changing results of the ADAURA and NeoADAURA trials.

Minimal residual disease negativity may negate the need to wait 5 to 10 years for updated findings to inform treatment decision-making in multiple myeloma.

Explore how ADCs, ctDNA monitoring, and new endocrine options reshape metastatic breast cancer care, as well as sequencing and toxicity tips from experts.

The panel discussed key considerations in the relapsed/refractory setting, including toxicity management and sequencing strategies for targeted agents.

Diane Simeone, MD, discussed efficacy results from the phase 3 RASolute 302 trial evaluating daraxonrasib in patients with metastatic pancreatic cancer.

Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.

Data from the phase 3 DREAMM-7 trial support the approval of belantamab mafodotin plus bortezomib and dexamethasone for patients in China.